Pacira BioSciences (PCRX) Stock Forecast & Price Target

$14.94

+0.29 (+1.98%)

(As of 12:13 PM ET)

Pacira BioSciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 9 Analyst Ratings

Based on 9 Wall Street analysts who have issued ratings for Pacira BioSciences in the last 12 months, the stock has a consensus rating of "Hold." Out of the 9 analysts, 2 have given a sell rating, 4 have given a hold rating, and 3 have given a buy rating for PCRX.

Consensus Price Target

$24.78
65.85% Upside

High Forecast	$57.00
Average Forecast	$24.78
Low Forecast	$8.00

According to the 9 analysts' twelve-month price targets for Pacira BioSciences, the average price target is $24.78. The highest price target for PCRX is $57.00, while the lowest price target for PCRX is $8.00. The average price target represents a forecasted upside of 65.85% from the current price of $14.94.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Hold	Hold	Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	10 Buy rating(s)	8 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$24.78	$24.78	$47.40	$58.00
Forecasted Upside	65.85% Upside	59.08% Upside	52.48% Upside	47.06% Upside

War on Elon Escalates… (Ad)

Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

Click here to learn how you can benefit from its widespread distribution.

PCRX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PCRX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Pacira BioSciences Stock vs. The Competition

Type	Pacira BioSciences	Medical Companies	S&P 500
Consensus Rating Score	2.11	2.77	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	65.85% Upside	968.13% Upside	6.74% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/13/2024	Truist Financial 1 of 5 stars	L. Sulewski Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Sell	$30.00 ➝ $8.00	-34.91%
8/12/2024	Piper Sandler 2 of 5 stars		Downgrade	Overweight ➝ Neutral	$42.00 ➝ $11.00	-5.98%
8/12/2024	Raymond James 4 of 5 stars	G. Nachman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/12/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Renza Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$37.00 ➝ $14.00	+19.66%
8/12/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Underweight	$45.00 ➝ $10.00	-14.53%
8/12/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$43.00 ➝ $22.00	+88.03%
Kamala Harris To Tank the Market? (Ad) URGENT ELECTION MELTDOWN WARNING From the former CIA advisor who predicted President Trump’s win in 2016… Click here now to see how to protect yourself.
8/12/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$57.00 ➝ $39.00	+233.33%
7/3/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Prasad Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$38.00 ➝ $25.00	+9.94%
2/8/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$57.00	+100.07%
8/3/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$50.00	+36.20%
1/6/2023	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Perform	$60.00 ➝ $52.00	+35.06%
12/14/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$54.00 ➝ $50.00	+17.70%
10/21/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$66.00	+29.79%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:42 PM ET.

PCRX Forecast - Frequently Asked Questions

What is Pacira BioSciences' forecast for 2024?: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Pacira BioSciences is $24.78, with a high forecast of $57.00 and a low forecast of $8.00.
Should I buy or sell Pacira BioSciences stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last year. There are currently 2 sell ratings, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PCRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PCRX, but not buy additional shares or sell existing shares.
Does Pacira BioSciences's stock price have much upside?: According to analysts, Pacira BioSciences's stock has a predicted upside of 59.08% based on their 12-month stock forecasts.
Has Pacira BioSciences been downgraded by Wall Street analysts recently?: Over the previous 90 days, Pacira BioSciences's stock had 5 downgrades by analysts.
What analysts cover Pacira BioSciences?: Pacira BioSciences has been rated by research analysts at Barclays, HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, Piper Sandler, Raymond James, Royal Bank of Canada, and Truist Financial in the past 90 days.
Do Wall Street analysts like Pacira BioSciences more than its competitors?: Analysts like Pacira BioSciences less than other "medical" companies. The consensus rating for Pacira BioSciences is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PCRX compares to other companies.